Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 685509 in diabetic kidney disease (phase II)
CTR20210956Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avenciguat in diabetic glomerulosclerosis, sponsored by Boehringer Ingelheim. Started May 2021; status: completed.
02
Drugs
avenciguat
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on CTR20210956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210956.